Introduction
Lithium carbonate has been used in therapeutics for more than a century. The introduction of this drug to psychiatry (Cade, 1949) was overshadowed by the emergence of phenothiazine therapy, but it now has an established place in the treatment of manic depressive affective psychosis (Task Force, 1975 (Strayhorn and Nash, 1977 (Vacaflor, 1975; Jefferson and Greist, 1977) . Significant neurotoxicity has appeared with normal serum levels (Strayhorn and Nash, 1977) and the elderly and schizophrenics are particularly liable to side effects (Shopsin, Johnson and Gershon, 1970) . Neurological disability in mild and moderate toxicity is usually readily reversible but severe neurotoxicity may be irreversible (Goldwater and Pollock, 1976) .
The first case above suggests that underlying neurological disorders may be precipitated and exacerbated by lithium therapy for incidental psychotic disturbances and this has been previously observed in a case of myasthenia (Neil, Himmelhock and Licata, 1976) . Although a patient with multiple sclerosis complicated by a manic illness was successfully treated with a short course of lithium (Kemp, Lion and Magram, 1977) , the present authors feel that lithium should be used with the utmost caution where psychotic illness is complicated by organic neurological disturbance, and only if other control measures have been unsuccessful. Red cell lithium levels may prove a more reliable indicator of incipient toxicity than the currently available serum levels (Hewick and Murray, 1976 ) and a series of therapeutic serum levels should not invite complacency. Intercurrent illness, impairment of renal function or concomitant diuretic therapy may precipitate toxicity in susceptible individuals.
Early detection of toxicity would be assisted by serial EEG monitoring of patients on lithium and perhaps by more frequent and more detailed clinical examination with urgent reassessment in the event of any abnormality being found.
